Payment overview · 2025
General Payments
$520.23
40 reported records · 6 companies
Healthcare provider profile · identity verified
Cheyanne Autry, APRN, FNP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ATLANTA, TX · NPI 1639806607
Verified facts
What the public records show
CMS Open Payments records show Cheyanne Autry, APRN, FNP-C received $520.23 in general payments during 2025 across 40 reported records.
ABBVIE INC. accounted for 51.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Vraylar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $267.22 | 51.4% | 33 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $136.53 | 26.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $55.75 | 10.7% | 3 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $32.21 | 6.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.46 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $14.06 | 2.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $520.23 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $222.76 | 25 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $136.53 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $44.46 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $37.05 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.04 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $32.21 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.06 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
118 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 325 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 294 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 227 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 174 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 49 |
| Omeprazole | Omeprazole | 162 | 38 |
| Lisinopril | Lisinopril | 160 | 46 |
| Metformin Hcl | Metformin Hcl | 139 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 35 |
| Trazodone Hcl | Trazodone Hcl | 126 | 33 |
| Buspirone Hcl | Buspirone Hcl | 123 | 32 |
| Eliquis | Apixaban | 118 | 21 |
| Losartan Potassium | Losartan Potassium | 117 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 116 | 24 |
| Potassium Chloride | Potassium Chloride | 115 | 38 |
| Furosemide | Furosemide | 109 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 25 |
| Clonidine Hcl | Clonidine Hcl | 96 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 96 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 96 | 26 |
| Ozempic | Semaglutide | 96 | 15 |
| Carvedilol | Carvedilol | 95 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 20 |
| Farxiga | Dapagliflozin Propanediol | 89 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 85 | 18 |
| Tramadol Hcl | Tramadol Hcl | 85 | 24 |
| Meloxicam | Meloxicam | 77 | 22 |
| Sertraline Hcl | Sertraline Hcl | 74 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 72 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 17 |
| Celecoxib | Celecoxib | 70 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 15 |
| Glimepiride | Glimepiride | 65 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 61 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 55 | 12 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Pregabalin | Pregabalin | 54 | 14 |
| Glipizide | Glipizide | 51 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 16 |
| Montelukast Sodium | Montelukast Sodium | 51 | suppressed |
| Simvastatin | Simvastatin | 51 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 13 |
| Alprazolam | Alprazolam | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 23 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 46 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 46 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 14 |
| Promethazine Hcl | Promethazine Hcl | 41 | suppressed |
| Spironolactone | Spironolactone | 41 | 12 |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | 11 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Olanzapine | Olanzapine | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | suppressed |
| Acyclovir | Acyclovir | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Azithromycin | Azithromycin | 28 | 28 |
| Estradiol | Estradiol | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Prednisone | Prednisone | 28 | 11 |
| Fluconazole | Fluconazole | 26 | 14 |
| Prazosin Hcl | Prazosin Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Methylprednisolone | Methylprednisolone | 25 | 23 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Vraylar | Cariprazine Hcl | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Perphenazine | Perphenazine | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 14 |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 20 | 19 |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Ofloxacin | Ofloxacin | 20 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 20 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Belsomra | Suvorexant | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 14 |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Actemra Actpen | Tocilizumab | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Elinest | Norgestrel-Ethinyl Estradiol | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $520.23 · 40 records | ABBVIE INC. | ABRYSVO, CAPVAXIVE, COMIRNATY, GARDASIL 9, INSPIRE, NURTEC ODT, Ozempic, PENBRAYA, PREVNAR 20, QULIPTA, Rybelsus, Senza, UBRELVY, VRAYLAR, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error